The FDA approved Telix Pharmaceuticals’ Pixclara (floretyrosine F-18; 18F-FET), making it the first FDA-approved FET-PET imaging agent for glioma and the first U.S.-approved PET radiopharmaceutical specifically targeting brain cancer. The approval positions Pixclara as a non-invasive imaging tool intended to distinguish recurrent or progressive glioma from treatment-related changes. The clearance comes after the FDA requested additional clinical evidence, and Telix emphasized its use in adults and pediatric patients at least 1 month old. For neuro-oncology, the development matters because imaging interpretation in treated brain tissue remains a key bottleneck for patient management and trial endpoints. For radiopharmaceutical strategy, this adds another milestone showing the FDA’s willingness to expand beyond therapeutics into precision diagnostics with imaging agents that target tumor biology rather than anatomy alone. The next steps are reimbursement positioning and integration into clinical imaging pathways that currently rely on conventional MRI timing and physician judgment.